A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy
- Authors
- Jang, Won Il; Bae, Sun Hyun; Kim, Mi-Sook; Han, Chul Ju; Park, Su Cheol; Kim, Sang Bum; Cho, Eung-Ho; Choi, Chul Won; Kim, Kyung Su; Hwang, Sangyoun; Kim, Jin Ho; Chang, A. Ram; Park, Younghee; Kim, Eun Seog; Kim, Woo Chul; Jo, Sunmi; Park, Hae Jin
- Issue Date
- 15-Jan-2020
- Publisher
- John Wiley & Sons Inc.
- Keywords
- endoscopy; hepatocellular carcinoma; stereotactic body radiotherapy; toxicity
- Citation
- Cancer, v.126, no.2, pp 363 - 372
- Pages
- 10
- Journal Title
- Cancer
- Volume
- 126
- Number
- 2
- Start Page
- 363
- End Page
- 372
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/3174
- DOI
- 10.1002/cncr.32502
- ISSN
- 0008-543X
1097-0142
- Abstract
- Background Although several prospective studies have reported the efficacy of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC), treatment-related toxicity varies and has not been determined. Therefore, the authors evaluated the safety and efficacy of SBRT for patients with HCC in a hepatitis B virus-endemic area. Methods This multicenter phase 2 trial enrolled patients with unresectable HCC. Patients received SBRT with 45 to 60 Gy in 3 fractions. To evaluate gastroduodenal toxicity, esophagogastroduodenoscopy (EGD) was performed before and 2 months after SBRT. The primary endpoint was treatment-related severe toxicity at 1 year after SBRT. The secondary endpoints were the 2-year local control, progression-free survival, and overall survival rates. Results In total, 74 patients were enrolled between January 2012 and April 2015, and 65 eligible patients were analyzed. One patient experienced radiation-induced liver disease with acute grade >= 3 toxicity 1 month after SBRT. In addition, 1 patient had a grade 3 esophageal ulcer with stenosis 5 months after SBRT. The actuarial rate of treatment-related severe toxicity at 1 year was 3%. The pre-SBRT and post-SBRT EGD findings were not significantly different among the 57 evaluable patients who underwent EGD. The 2-year and 3-year local control rates were 97% and 95%, respectively. The progression-free and overall survival rates were 48% and 84% at 2 years, respectively, and 36% and 76% at 3 years, respectively. Conclusions With a median follow-up of 41 months, this prospective multicenter study demonstrated that SBRT for patients with HCC is well tolerated and is an effective treatment modality.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Radiation Oncology > 1. Journal Articles
- College of Medicine > Department of Radiation Oncology > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/3174)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.